Solid Biosciences (NASDAQ:SLDB) CFO Sells $95,202.52 in Stock

Solid Biosciences Inc. (NASDAQ:SLDB) CFO Kevin Tan sold 14,783 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total transaction of $95,202.52. Following the completion of the sale, the chief financial officer directly owned 94,201 shares of the company’s stock, valued at approximately $606,654.44. The trade was a 13.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Kevin Tan also recently made the following trade(s):

• On Monday, February 2nd, Kevin Tan sold 26,837 shares of Solid Biosciences stock. The shares were sold at an average price of $6.44, for a total value of $172,830.28.
• On Tuesday, January 13th, Kevin Tan sold 5,704 shares of Solid Biosciences stock. The shares were sold at an average price of $5.27, for a total value of $30,060.08.

Solid Biosciences Trading Up 4.7%

NASDAQ SLDB opened at $6.52 on Monday. The firm’s 50 day simple moving average is $5.84 and its 200 day simple moving average is $5.71. The firm has a market capitalization of $507.97 million, a price-to-earnings ratio of -2.62 and a beta of 2.67. Solid Biosciences Inc. has a 1 year low of $2.41 and a 1 year high of $7.37.

Institutional Trading of Solid Biosciences

Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc increased its stake in shares of Solid Biosciences by 208.6% during the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after purchasing an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after acquiring an additional 4,534 shares in the last quarter. Creative Planning bought a new stake in shares of Solid Biosciences during the 2nd quarter worth $57,000. Russell Investments Group Ltd. boosted its stake in Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after buying an additional 5,991 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Solid Biosciences by 233.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after buying an additional 10,585 shares during the period. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Wall Street Analysts Forecast Growth

SLDB has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Solid Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a research note on Wednesday, December 17th. Barclays set a $9.00 price target on shares of Solid Biosciences and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a research report on Wednesday, January 14th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.70.

Solid Biosciences News Summary

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
• Neutral Sentiment: Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.
• Negative Sentiment: CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. CEO Sale SEC Filing
• Negative Sentiment: CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. CFO Sale SEC Filing
• Negative Sentiment: COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. COO Sale SEC Filing
• Negative Sentiment: CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. CTO Sale SEC Filing
• Negative Sentiment: Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. Director/Insider Sales SEC Filings

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.